{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:31:15Z","timestamp":1792218675622,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2684,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mds314","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T08:24:49Z","timestamp":1347870289000},"page":"x313-x319","source":"Crossref","is-referenced-by-count":68,"special_numbering":"S10","title":["Prevention and handling of acute allergic and infusion reactions in oncology"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Joerger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mds314_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.iac.2004.03.010","article-title":"Classification and epidemiology of hypersensitivity drug reactions","volume":"24","author":"Demoly","year":"2004","journal-title":"Immunol allergy Clin North am"},{"issue":"2","key":"10.1093\/annonc\/mds314_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tox.2004.12.027","article-title":"anaphylactic reactions\u2013\u2013value of skin and provocation tests","volume":"209","author":"Demoly","year":"2005","journal-title":"Toxicology"},{"issue":"5","key":"10.1093\/annonc\/mds314_bb0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","article-title":"Hypersensitivity reactions to chemotherapeutic drugs","volume":"24","author":"Shepherd","year":"2003","journal-title":"Clin Rev allergy Immunol"},{"issue":"4","key":"10.1093\/annonc\/mds314_bb0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.mcna.2010.03.002","article-title":"The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization","volume":"94","author":"Pagani","year":"2010","journal-title":"Med Clin North am"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.NAN.0000270674.13439.5b","article-title":"The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses\u2019 perspectives","volume":"30","author":"Colwell","year":"2007","journal-title":"J Infus Nurs"},{"key":"10.1093\/annonc\/mds314_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7150\/jca.2.153","article-title":"a retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature","volume":"2","author":"Demoor","year":"2011","journal-title":"J Cancer"},{"issue":"10","key":"10.1093\/annonc\/mds314_bb0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","article-title":"Prevention and management of antineoplastic-induced hypersensitivity reactions","volume":"24","author":"Zanotti","year":"2001","journal-title":"Drug Saf"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000178163","article-title":"Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience","volume":"76","author":"Polyzos","year":"2009","journal-title":"Oncology"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00520-006-0107-9","article-title":"Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication","volume":"15","author":"Lee","year":"2007","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11882-008-0011-0","article-title":"Hypersensitivity reactions to oxaliplatin and other antineoplastic agents","volume":"8","author":"Syrigou","year":"2008","journal-title":"Curr allergy asthma Rep"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000107467","article-title":"Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin","volume":"145","author":"Pagani","year":"2008","journal-title":"Int arch allergy Immunol"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cncr.11901","article-title":"Hypersensitivity and idiosyncratic reactions to oxaliplatin","volume":"100","author":"Bhargava","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/ijgc-00009577-200501000-00003","article-title":"Carboplatin hypersensitivity","volume":"15","author":"Sliesoraitis","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1093\/annonc\/mds314_bb0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1525-1438.2007.01063.x","article-title":"analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1093\/annonc\/mds314_bb0090","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J allergy Clin Immunol"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mds314_bb0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s101470200056","article-title":"anaphylaxis to cisplatin following nine previous uncomplicated cycles","volume":"7","author":"Basu","year":"2002","journal-title":"Int J Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mds314_bb0110","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","article-title":"Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents","volume":"102","author":"Lee","year":"2009","journal-title":"ann allergy asthma Immunol"},{"issue":"9","key":"10.1093\/annonc\/mds314_bb0120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1345\/aph.10287","article-title":"Prophylaxis for paclitaxel hypersensitivity reactions","volume":"35","author":"Kintzel","year":"2001","journal-title":"ann Pharmacother"},{"issue":"1","key":"10.1093\/annonc\/mds314_bb0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2005.08.004","article-title":"Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program","volume":"100","author":"Dizon","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0130","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.critrevonc.2006.07.009","article-title":"Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia","volume":"61","author":"Narta","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1093\/annonc\/mds314_bb0135","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1365-2141.2001.03009.x","article-title":"Pharmacokinetics of native Escherichia coli asparaginase (asparaginase medac) and hypersensitivity reactions in aLL-BFM 95 reinduction treatment","volume":"114","author":"Muller","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mds314_bb0140","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.leu.2403351","article-title":"asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia","volume":"18","author":"Hak","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"10.1093\/annonc\/mds314_bb0145","first-page":"458","article-title":"Hypersensitivity reactions","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mds314_bb0150","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1993.11.6.1080","article-title":"acute hypersensitivity reactions to etoposide in a VEPa regimen for Hodgkin's disease","volume":"11","author":"Hudson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds314_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MPH.0b013e318199388c","article-title":"Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma","volume":"31","author":"Ozguven","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1093\/annonc\/mds314_bb0160","first-page":"548","article-title":"Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease","volume":"10","author":"Hani","year":"2000","journal-title":"Eur J Dermatol"},{"issue":"1 Pt 1","key":"10.1093\/annonc\/mds314_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0091-6749(96)70279-8","article-title":"allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients","volume":"97","author":"Popescu","year":"1996","journal-title":"J allergy Clin Immunol"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/pbc.20617","article-title":"adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide","volume":"49","author":"Khaw","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1093\/annonc\/mds314_bb0175","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"issue":"1 Suppl","key":"10.1093\/annonc\/mds314_bb0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/07.CJON.S1.37-42","article-title":"Cytokine-release syndrome: overview and nursing implications","volume":"11","author":"Breslin","year":"2007","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"10.1093\/annonc\/mds314_bb0185","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"10.1093\/annonc\/mds314_bb0190","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mds314_bb0195","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosis, assessment, and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"10.1093\/annonc\/mds314_bb0200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaci.2010.06.022","article-title":"The diagnosis and management of anaphylaxis practice parameter: 2010 update","volume":"126","author":"Lieberman","year":"2010","journal-title":"J allergy Clin Immunol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_10\/x313\/6678772\/mds314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:32:05Z","timestamp":1582205525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419417675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":39,"alternative-id":["S0923753419417675"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds314","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}